FDA Advisory Committee Votes Unanimously to Recommend Approval of Tetrabenazine for Chorea Associated with Huntington's Disease

Thu Dec 6, 2007 5:46pm EST

WASHINGTON, Dec. 6 /PRNewswire/ -- An advisory committee to the U.S. Food and Drug Administration (FDA) today voted unanimously to recommend the approval of tetrabenazine, which would be the first drug approved in the United States to treat chorea associated with Huntington disease (HD).

"The advisory committee's support of tetrabenazine represents an important advancement for Huntington disease patients, caregivers, advocates and physicians who treat this devastating disease," said George F. Horner III, president and chief executive officer of Prestwick. "We are committed to continuing to work with the FDA to secure full approval of tetrabenazine."

While the FDA is not required to follow the advice of its advisory committees, they generally do.

HD is a devastating neurodegenerative disease that causes progressive movement disorders, cognitive dysfunction and behavioral changes, that is ultimately a fatal condition. Chorea is characterized by excessive, involuntary and repetitive movements which are the most visible and dangerous manifestations of Huntington disease.

"Patients and physicians do not have any approved treatments to alleviate this disorder or any aspect of Huntington disease," said Frederick Marshall, MD, chief of the geriatric neurology unit at the University of Rochester, who presented data on behalf of Prestwick. "We are hopeful that the FDA will adhere to the recommendations made by the committee to quickly bring tetrabenazine to the patients for whom we care."

Chorea affects over 30,000 Americans, interfering with their ability to perform activities of daily living, including dressing, bathing and caring for themselves. Currently, there are no treatments to stop or reverse the onset or progression of HD and there are no FDA-approved drugs for chorea.

About Tetrabenazine

Tetrabenazine is an investigational compound for the treatment of chorea associated with HD. A highly selective and reversible centrally-acting dopamine depleting drug, tetrabenazine works by inhibiting a molecule known as VMAT2 (vesicular monoamine transporter 2).

Adverse events reported with tetrabenazine, most of which were addressed by titrating down the dose, included depression, akathisia, parkinsonism and sedation. Tetrabenazine's effects are largely reversible and manageable.

The FDA has issued an approvable letter for the compound. Tetrabenazine has been designated as an "orphan drug" by the FDA and has been granted "fast track" status.

About Prestwick

Prestwick Pharmaceuticals, a privately-held pharmaceutical company headquartered in Washington, is currently managing a portfolio of pipeline product candidates being studied for CNS conditions with significant unmet needs, including Huntington's disease, Parkinson's disease, restless legs syndrome, schizophrenia, autism, Alzheimer's disease and sleep apnea. For more information, go to www.prestwickpharma.com

SOURCE Prestwick Pharmaceuticals
Jessica Carlso
, +1-312-515-0501
jcarlson@wcpglobal.com
for Prestwick Pharmaceuticals
© Reuters2007All rights reserved

FDA Panel Vote Backs Prestwick's HD Drug

By Donna Young
Washington Editor

Federal advisers Thursday said that, despite its risks, the FDA should approve Prestwick Pharmaceuticals' Xenazine (tetrabenazine) as a treatment to control the involuntary jerky movements, known as chorea, associated with Huntington's disease.

Study results showed that there was a clear drug-related increase in significant adverse events, including parkinsonism, akathisia, depression and dysphagia, associated with Xenazine use.

About 15 percent of patients receiving the drug in one study experienced depression, compared with no patients in the placebo group, the FDA said. One study participant committed suicide while on Xenazine. But regulators noted that there is a high prevalence of suicide in Huntington's disease and that twice as many patients were randomized in the study to receive the drug.

The FDA's Peripheral and Central Nervous Systems Advisory Committee Thursday voted unanimously that the adverse effects associated with Xenazine did not outweigh the benefits of using the drug to control chorea.

Because some of the drug-related reactions also are symptoms of Huntington's disease itself, regulators expressed concern that a patient's physician may not be able to identify the adverse event as being drug-related.

Prestwick argued that because the response to Xenazine is rapid, often being observed within days, physicians and patients can determine if the efficacy achieved outweighs potential adverse effects of treatment. The firm contended that the adverse effects associated with Xenazine can be managed through careful titration and dose adjustment.

The committee agreed, stating the FDA's concerns about adverse effects could be remedied by adding statements in drug labeling noting that Xenazine should be started at the lowest dosage necessary to control chorea.

Study investigator Peter Como, associate professor of neurology, psychiatry and brain and cognitive sciences at the University of Rochester in New York, said that most physicians prescribing the drug, "If they know their patient well enough," would more than likely decrease the dosage if the prescriber recognized a progression in the disease. However, he told BioWorld Today, "Even the most expert clinicians with 100 percent confidence may not always be able to pick out" the natural disease progression from an adverse event.

While the FDA determined Xenazine was effective in treating Huntington's chorea, the agency was concerned about secondary outcomes of the supporting studies that showed that patients on placebo performed better in terms of motor function and behavior.

However, panelists unanimously agreed that the lack of a beneficial effect of Xenazine on numerous measures of function and cognition did not outweigh the drug's effectiveness in treating chorea.

Como said that the secondary outcomes identified in the study may be more of a result of the need for more sensitive scales to measure such outcomes.

There currently is no FDA-approved treatment for chorea associated with Huntington's disease, a fatal neurodegenerative disease marked by involuntary movements, cognitive decline and behavioral disruption that affects about 30,000 Americans.

Drugs that block dopamine transmission, neuroleptics or reserpine, currently are prescribed for the condition, but central and peripheral adverse effects, including a condition known as tardive dyskinesia that actually can be caused by use of such drugs, limit their use, said Nancy Wexler, president of the Hereditary Disease Foundation.

Thursday's recommendation to approve Xenazine, Wexler told BioWorld Today, is not only "fantastic," but an "historic" event for patients.

Approval of the drug not only will help U.S. patients gain access to Xenazine, but also will ensure that insurers cover the drug, said Wexler, who, along with her father, discovered the Huntington's disease gene.

Tetrabenazine initially was developed by Basel, Switzerland-based F. Hoffmann-La Roche in the mid-1950s as an antipsychotic drug to treat schizophrenia. However, it never gained widespread use for that condition and later was found to be effective in treating chorea, especially for patients with Huntington's disease.

The drug is approved for Huntington's disease in several European countries, including Germany and France, and also is approved in other nations outside the U.S. to treat organic movement disorders and tardive dyskinesia, noted Wexler, a professor of neuropsychology at Columbia University in New York.

She praised Prestwick for seeking U.S. approval of the product, which has been designated by the FDA as an orphan drug. "Patients in the United States will finally have a chance to use it," Wexler said.

The FDA is expected to take approval action on Xenazine in early 2008.

BioWorld Today December 7, 2007